The Cancer Questions Project, Part 18: Joseph Jurcic
Dr. Joseph Jurcic specializes in the research of acute myeloid leukemia, radioimmunotherapy with alpha and beta particle-emitting radioisotopes, monoclonal antibody therapy for leukemia, and the molecular monitoring of minimal residual disease. His work focuses on the treatment of acute and chronic leukemias, myeloproliferative neoplasms, and myelodysplastic syndrome. He received the 2001 Louis and Allston Boyer Young Investigator Award for Distinguished Achievement in Biomedical Research from Memorial Sloan-Kettering Cancer Center. Dr. Jurcic is currently Professor of Medicine at Columbia University Medical Center and Director of the Hematologic Malignancies Section of the Division of Hematology/Oncology with over 80 articles and book chapters to his name.
The Cancer Questions Project, Part 17: Benjamin Ebert
Dr. Benjamin Ebert is remarkable for his leadership in describing the genomic landscape of adult myelodysplastic syndrome (MDS), including identifying critical new roles for ribosomal dysfunction. His laboratory discovered the molecular basis of lenalidomide activity in MDS as well as multiple myeloma. Recent studies have identified clonal hematopoiesis and its contribution to both hematologic malignancies and cardiovascular disease. Along with human genetic studies, Dr. Ebert’s lab has made significant contributions to understanding the biological basis of the transformation of hematopoietic cells by somatic mutations. Currently, he is chair of the medical oncology department at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School.
The Cancer Questions Project, Part 16: Gary Schwartz
Dr. Gary Schwartz is a recognized leader in the field of translational research and has been able to connect the basic and clinical science elements of drug development. His research focuses on the identification of new targeted agents for cancer therapy, especially in the treatment of sarcoma and melanoma. He earned NCI K24 and K12 Clinical Oncology Research Career Development Awards aimed at the mentoring of medical trainees in translational research. Moreover, he has authored about 200 papers and 17 book chapters in the field of basic and clinical cancer research. He currently serves as the Chief of the Division of Hematology and Oncology and Deputy Director of the Herbert Irving Comprehensive Cancer Center at Columbia University School of Medicine.
The Cancer Questions Project, Part 15: Robert “Bob” Gallo
Dr Robert Gallo, a biomedical researcher, is renowned for his role in the discovery of human immunodeficiency virus (HIV) as the infectious agent responsible for AIDS and in the development of HIV blood tests. He co-founded Profectus BioSciences, Inc., a biotechnology company. Profectus develops and commercializes technologies to reduce the morbidity and mortality caused by human viral diseases. He is also a co-founder and scientific director of Global Virus Network. He is the director and co-founder of the Institute of Human Virology at the University of Maryland School of Medicine. In November 2011, Dr Gallo was named the first Homer & Martha Gudelsky Distinguished Professor in Medicine.
The Cancer Questions Project, Part 14: Larry Norton
Dr. Larry Norton, a breast oncologist, is well-known as a leader in the development of drug treatments for breast cancer. His research has established the importance of using sequential combinations of drugs — a strategy aimed to overcome different drug sensitivities among the cells in a tumor. He has served in leadership positions in several national cancer-related organizations, including serving as president of the American Society of Clinical Oncology (ASCO) in 2001-2002, and is chairman of the board of directors of the ASCO Foundation. Currently, Dr. Norton is serving as the Senior Vice President at Memorial Sloan Kettering Cancer Center and a Professor of Medicine at Weill-Cornell Medical College with over 350 published articles and book chapters to his name.
